Z-VAD-FMK C22H30FN307
To Order Contact us: stephen@expresspharmapulse.com
Z-VAD(OMe)-FMK |
27313 |
BPS Bioscience |
5 mg |
EUR 480 |
Description: Z-VAD(OMe)-FMK is a cell permeable, irreversible pan-caspase inhibitor and anti-apoptotic agent. It has been shown to inhibit Fas-mediated apoptosis in Jurkat T cells and apoptosis in THP.1 cells induced by diverse stimuli (including cycloheximide, thapsigargin, etoposide and staurosporine). Inhibits caspases 1, 3, 4, and 7. |
Z-VAD-FMK, Methyl Ester |
27017 |
BPS Bioscience |
1 mg |
EUR 165 |
Description: Z-VAD(OMe)-FMK is a cell permeable, irreversible pan-caspase inhibitor and anti-apoptotic agent. It has been shown to inhibit Fas-mediated apoptosis in Jurkat T cells and apoptosis in THP.1 cells induced by diverse stimuli (including cycloheximide, thapsigargin, etoposide and staurosporine). Inhibits caspases 1, 3, 4, and 7._x000D__x000D_ _x000D_ |
Caspase-Family Inhibitor Z-VAD-FMK |
1010-100 |
Biovision |
each |
EUR 235.2 |
Caspase-Family Inhibitor Z-VAD-FMK |
1010-20C |
Biovision |
each |
EUR 235.2 |
SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
13472 |
AAT Bioquest |
25 Tests |
EUR 158.4 |
|
SRB-VAD-FMK [Sulforhodamine B-VAD-FMK] |
13482 |
AAT Bioquest |
100 Tests |
EUR 211 |
Z-VAD-FMK (Pan-specific caspase inhibitor) |
SIH-557-1MG |
Stressmarq |
1 mg |
EUR 231.6 |
Description: The substance Z-VAD-FMK is a pan-specific caspase inhibitor. It is synthetically produced and has a purity of >98%. The pure substance is lyophilized solid or wax which is May be dissolved in DMSO (10 mg/ml). |
FITC-VAD-FMK |
9497-100 |
Biovision |
each |
EUR 430.8 |
Biotin-VAD-FMK |
1123-20C |
Biovision |
each |
EUR 392.4 |
Z-YVAD-FMK |
A8955-1 |
ApexBio |
1 mg |
EUR 282 |
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
Z-YVAD-FMK |
A8955-5 |
ApexBio |
5 mg |
EUR 616.8 |
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
Z-YVAD-FMK |
A8955-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 1326 |
Description: Z-YVAD-FMK is a potent cell-permeable and irreversible inhibitor of caspase-1.In Caco-2 cells, Z-YVAD-FMK significantly decreased the growth inhibition induced by butyrate. |
Z-FA-FMK |
A8170-1 |
ApexBio |
1 mg |
EUR 142.8 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-FA-FMK |
A8170-10 |
ApexBio |
10 mg |
EUR 560.4 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-FA-FMK |
A8170-25 |
ApexBio |
25 mg |
EUR 616.8 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-FA-FMK |
A8170-5 |
ApexBio |
5 mg |
EUR 338.4 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-FA-FMK |
A8170-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 408 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-FA-FMK |
A8170-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: Z-FA-FMK is a control peptidic fluoromethylketone (boc-Thr-CH2F), and inhibitor to calpain (Ac-Leu-Leu-norleucinal), cathepsin B (Z-Phe-Ala-CH2F), and CPP32-like proteases (Z-DEVD-CH2F) [1]. |
Z-DEVD-FMK |
A1920-1 |
ApexBio |
1 mg |
EUR 135.6 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-10 |
ApexBio |
10 mg |
EUR 408 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-25 |
ApexBio |
25 mg |
EUR 616.8 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-5 |
ApexBio |
5 mg |
EUR 268.8 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 351.6 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DEVD-FMK |
A1920-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: Z-DEVD-FMK is a tetrapeptide caspase inhibitor that is considered relatively selective for caspase-31, 2 and has been widely used in in vitro and in vivo models of acute injury to delineate roles for caspase 3 in neuronal cell death. |
Z-DQMD-FMK |
A1921-1 |
ApexBio |
1 mg |
EUR 135.6 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-10 |
ApexBio |
10 mg |
EUR 408 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-25 |
ApexBio |
25 mg |
EUR 616.8 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-5 |
ApexBio |
5 mg |
EUR 268.8 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 518.4 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-DQMD-FMK |
A1921-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: Inhibition of caspase-3 processing by Z-DQMD-FMK (Z-Asp(OMe)-Gln-Met-Asp(OMe)-fluoromethylketone) did not restore cell number in the zinc-deficient group, but resulted in processing of full-length PKC-? to a 56-kDa fragment1. |
Z-VDVAD-FMK |
A1922-1 |
ApexBio |
1 mg |
EUR 212.4 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-10 |
ApexBio |
10 mg |
EUR 756 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-25 |
ApexBio |
25 mg |
EUR 1173.6 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-5 |
ApexBio |
5 mg |
EUR 477.6 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VDVAD-FMK |
A1922-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: Jurkat T-lymphocytes treated with an irreversible caspase-2 inhibitor, benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-fluoromethyl ketone (Z-VDVAD-FMK), or stably transfected with pro-caspase-2 antisense (Casp-2/AS) are refractory to cytochrome c release stimulated by etoposide1. |
Z-VEID-FMK |
A1923-1 |
ApexBio |
1 mg |
EUR 212.4 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-10 |
ApexBio |
10 mg |
EUR 756 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-25 |
ApexBio |
25 mg |
EUR 1173.6 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-5 |
ApexBio |
5 mg |
EUR 477.6 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-VEID-FMK |
A1923-S |
ApexBio |
Evaluation Sample |
EUR 97.2 |
Description: When compared to other caspase inhibitors, Z-DRHD-FMK inhibited caspase 6 activity more effectively than the general caspase inhibitor Z-Val-Ala-Asp (OMe)-fluoromethy ketone (Z-VAD-FMK) or the caspase 6 inhibitor Z-Val-Glu(Ome)-Ile-Asp(OMe)-fluoromethyl ketone (Z-VEID-FMK). |
Z-WEHD-FMK |
A1924-1 |
ApexBio |
1 mg |
EUR 135.6 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-10 |
ApexBio |
10 mg |
EUR 408 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-25 |
ApexBio |
25 mg |
EUR 616.8 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-WEHD-FMK |
A1924-5 |
ApexBio |
5 mg |
EUR 268.8 |
Description: Treatment of infected cells with pan-caspase inhibitor IV and Z-WEHD-FMK, an inhibitor of inflammatory caspases, elicited a near-complete blockage of C. trachomatis-induced cleavage of golgin-84. |
Z-IETD-FMK |
B3232-1 |
ApexBio |
1 mg |
EUR 393.6 |
Description: Z-IETD-FMK is an inhibitor of caspase 8 [1].Z-IETD-FMK inhibits T cell proliferation induced by PHA or anti-CD3 plus anti-CD28 without toxicity of resting T cells. |
Z-VAD-FMK C22H30FN307